ALT5 Sigma (ALTS) Competitors $7.10 -0.19 (-2.61%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$7.35 +0.25 (+3.52%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. ATYR, SLDB, TERN, SIGA, PRTC, TRML, RZLT, KMDA, CGEM, and RGNXShould you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include aTyr Pharma (ATYR), Solid Biosciences (SLDB), Terns Pharmaceuticals (TERN), Siga Technologies (SIGA), PureTech Health (PRTC), Tourmaline Bio (TRML), Rezolute (RZLT), Kamada (KMDA), Cullinan Therapeutics (CGEM), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. ALT5 Sigma vs. Its Competitors aTyr Pharma Solid Biosciences Terns Pharmaceuticals Siga Technologies PureTech Health Tourmaline Bio Rezolute Kamada Cullinan Therapeutics REGENXBIO ALT5 Sigma (NASDAQ:ALTS) and aTyr Pharma (NASDAQ:ATYR) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Which has better valuation & earnings, ALTS or ATYR? ALT5 Sigma has higher revenue and earnings than aTyr Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$18.05M6.87-$6.24MN/AN/AaTyr Pharma$230K2,147.61-$64.02M-$0.81-6.85 Do analysts prefer ALTS or ATYR? aTyr Pharma has a consensus target price of $20.20, indicating a potential upside of 263.96%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media prefer ALTS or ATYR? In the previous week, aTyr Pharma had 6 more articles in the media than ALT5 Sigma. MarketBeat recorded 8 mentions for aTyr Pharma and 2 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.63 beat aTyr Pharma's score of 0.59 indicating that ALT5 Sigma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ALTS or ATYR? ALT5 Sigma has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ALTS or ATYR? 6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 4.9% of ALT5 Sigma shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is ALTS or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to ALT5 Sigma's net margin of -38.58%. aTyr Pharma's return on equity of -87.09% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-38.58% -113.79% -8.96% aTyr Pharma N/A -87.09%-64.77% SummaryaTyr Pharma beats ALT5 Sigma on 9 of the 15 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$127.25M$8.01B$12.31B$9.47BDividend YieldN/A4.68%5.53%3.99%P/E RatioN/A19.0119.0619.95Price / Sales6.875.8626.22100.93Price / CashN/A21.8321.8458.97Price / Book14.492.792.275.90Net Income-$6.24M$314.15M$998.01M$258.42M7 Day Performance-3.01%3.17%0.88%2.11%1 Month Performance-24.31%19.31%4.39%12.44%1 Year Performance255.00%26.66%540.85%19.55% ALT5 Sigma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSALT5 Sigma0.1425 of 5 stars$7.10-2.6%N/A+262.2%$127.25M$18.05M0.00170ATYRaTyr Pharma2.3002 of 5 stars$5.24-8.2%$20.20+285.5%+187.6%$508.21M$230K-6.4753High Trading VolumeSLDBSolid Biosciences3.2936 of 5 stars$6.23-2.2%$15.10+142.4%-24.4%$493.77M$8.09M-2.08100TERNTerns Pharmaceuticals3.6241 of 5 stars$6.00+6.4%$15.63+160.4%-30.1%$492.58MN/A-5.5040Positive NewsSIGASiga Technologies2.1158 of 5 stars$6.85flatN/A-27.4%$489.37M$138.72M10.2240News CoverageUpcoming EarningsOptions VolumePRTCPureTech Health2.6479 of 5 stars$18.23-7.3%$45.00+146.9%-16.2%$472.52M$4.83M0.00100Positive NewsUpcoming EarningsTRMLTourmaline Bio2.1561 of 5 stars$18.86+3.5%$49.33+161.6%+13.8%$468.24MN/A-5.8844Positive NewsRZLTRezolute2.6388 of 5 stars$5.37-0.2%$11.83+120.4%+26.5%$468.04MN/A-4.6740KMDAKamada3.326 of 5 stars$7.64-2.1%$13.00+70.2%+33.7%$448.54M$160.95M26.34360CGEMCullinan Therapeutics1.4507 of 5 stars$8.11+7.8%$30.00+269.9%-59.0%$443.79MN/A-2.7930Positive NewsRGNXREGENXBIO4.2711 of 5 stars$8.57+0.9%$31.63+269.0%-33.1%$425.86M$83.33M-2.76370News CoveragePositive News Related Companies and Tools Related Companies ATYR Alternatives SLDB Alternatives TERN Alternatives SIGA Alternatives PRTC Alternatives TRML Alternatives RZLT Alternatives KMDA Alternatives CGEM Alternatives RGNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.